You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropranolol
Accession NumberDB00571  (APRD00194)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem]
Structure
Thumb
Synonyms
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
beta-Propranolol
Propanalol
Propanolol
Propranolol
Propranololo
Propranololum
β-Propranolol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Detensol Tab 10mgTablet10 mgOralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Detensol Tab 120mgTablet120 mgOralDesbergers LtÉe, Division Of Technilab Inc.1981-12-311999-09-17Canada
Detensol Tab 40mgTablet40 mgOralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Detensol Tab 80mgTablet80 mgOralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Dom-propranolol TabletsTablet40 mgOralDominion Pharmacal1996-12-312016-10-25Canada
Dom-propranolol TabletsTablet10 mgOralDominion Pharmacal1996-12-312016-10-25Canada
Dom-propranolol Tablets - 80mgTablet80 mgOralDominion Pharmacal1996-12-312016-10-25Canada
HemangeolSolution4.28 mg/mLOralPierre Fabre Pharmaceuticals, Inc.2014-04-14Not applicableUs
HemangiolSolution3.75 mgOralPierre Fabre Dermo Cosmetique Canada IncNot applicableNot applicableCanada
Inderal 20 Tab 20mgTablet20 mgOralAyerst Laboratories1984-12-311999-04-12Canada
Inderal 80 TabTablet80 mgOralAyerst Laboratories1974-12-311996-09-10Canada
Inderal Injectable Liq 1mg/mlLiquid1 mgIntravenousWyeth Ayerst Canada Inc.1995-12-312003-04-17Canada
Inderal LACapsule, extended release80 mg/1OralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LACapsule, extended release120 mg/1OralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LACapsule, extended release160 mg/1OralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LACapsule, extended release60 mg/1OralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LA Cap 160mgCapsule, extended release160 mgOralAyerst Laboratories1980-12-311996-09-10Canada
Inderal LA Cap 80mgCapsule, extended release80 mgOralAyerst Laboratories1982-12-311996-09-10Canada
Inderal Tab 120mgTablet120 mgOralAyerst Laboratories1979-12-311997-08-15Canada
Inderal XLCapsule, extended release80 mg/1OralMist Pharmaceuticals, Llc2014-02-01Not applicableUs
Inderal XLCapsule, extended release120 mg/1OralMist Pharmaceuticals, Llc2014-02-01Not applicableUs
Inderal-10 Tab 10mgTablet10 mgOralWyeth Ayerst Canada Inc.1994-12-312004-07-27Canada
Inderal-120 Tab 120mgTablet120 mgOralWyeth Ayerst Canada Inc.1996-10-252001-02-02Canada
Inderal-20 Tab 20mgTablet20 mgOralWyeth Ayerst Canada Inc.1994-12-312002-05-17Canada
Inderal-40 Tab 40mgTablet40 mgOralWyeth Ayerst Canada Inc.1993-12-312002-05-17Canada
Inderal-80 Tab 80mgTablet80 mgOralWyeth Ayerst Canada Inc.1996-10-252001-05-07Canada
Inderal-LACapsule, extended release60 mgOralPfizer Canada Inc1995-12-31Not applicableCanada
Inderal-LACapsule, extended release80 mgOralPfizer Canada Inc1994-12-31Not applicableCanada
Inderal-LACapsule, extended release120 mgOralPfizer Canada Inc1994-12-31Not applicableCanada
Inderal-LACapsule, extended release160 mgOralPfizer Canada Inc1994-12-31Not applicableCanada
Innopran XLCapsule, extended release80 mg/1OralAkrimax Pharmaceuticals, LLC2013-06-01Not applicableUs
Innopran XLCapsule, extended release120 mg/1OralAkrimax Pharmaceuticals, LLC2013-06-01Not applicableUs
Novo-pranol Tab 120mgTablet120 mgOralNovopharm Limited1982-12-312005-08-10Canada
Nu-propranolol Tab 10mgTablet10 mgOralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 120mgTablet120 mgOralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 20mgTablet20 mgOralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 40mgTablet40 mgOralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 80mgTablet80 mgOralNu Pharm Inc1993-12-312012-09-04Canada
PMS-propranolol Tablets 10mgTablet10 mgOralPharmascience Inc1983-12-31Not applicableCanada
PMS-propranolol Tablets 120mgTablet120 mgOralPharmascience Inc1983-12-31Not applicableCanada
PMS-propranolol Tablets 40mgTablet40 mgOralPharmascience Inc1983-12-31Not applicableCanada
PMS-propranolol Tablets 80mgTablet80 mgOralPharmascience Inc1983-12-31Not applicableCanada
Propranolol Hydrochloride ERCapsule, extended release60 mg/1OralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release120 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release80 mg/1OralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release80 mg/1OralA S Medication Solutions2009-02-25Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release120 mg/1OralUnit Dose Services1983-04-19Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release80 mg/1OralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release160 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release120 mg/1OralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release60 mg/1OralAmerican Health Packaging2013-07-05Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release160 mg/1OralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERCapsule, extended release80 mg/1OralAmerican Health Packaging2013-07-05Not applicableUs
Propranolol Hydrochloride Injection USPSolution1 mgIntravenousSandoz Canada Incorporated1996-10-04Not applicableCanada
Propranolol Hydrochloride Tablet 40mgTablet40 mgOralD.C. Labs Limited1982-12-312003-07-11Canada
Propranolol Tab 10mgTablet10 mgOralPro Doc Limitee1980-12-312010-07-13Canada
Propranolol Tab 40mgTablet40 mgOralPro Doc Limitee1980-12-312010-07-13Canada
Propranolol Tab 80mgTablet80 mgOralPro Doc Limitee1980-12-312010-07-13Canada
Propranolol-120 Tab 120mgTablet120 mgOralPro Doc Limitee1987-12-312010-07-13Canada
Propranolol-20 Tab 20mgTablet20 mgOralPro Doc Limitee1987-12-312010-07-13Canada
Teva-propranololTablet10 mgOralTeva Canada Limited1981-12-31Not applicableCanada
Teva-propranololTablet20 mgOralTeva Canada Limited1987-12-31Not applicableCanada
Teva-propranololTablet40 mgOralTeva Canada Limited1981-12-31Not applicableCanada
Teva-propranololTablet80 mgOralTeva Canada Limited1981-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Propranolol Tab 10mgTablet10 mgOralApotex Inc1980-12-31Not applicableCanada
Apo Propranolol Tab 120mgTablet120 mgOralApotex Inc1981-12-31Not applicableCanada
Apo Propranolol Tab 40mgTablet40 mgOralApotex Inc1980-12-31Not applicableCanada
Apo Propranolol Tab 80mgTablet80 mgOralApotex Inc1980-12-31Not applicableCanada
Apo-propranolol Tab 20mgTablet20 mgOralApotex Inc1986-12-31Not applicableCanada
PropranololInjection1 mg/mLIntravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
PropranololInjection, solution1 mg/mLIntravenousAPP Pharmaceuticals, LLC2001-09-07Not applicableUs
PropranololInjection1 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2011-02-22Not applicableUs
PropranololTablet10 mg/1OralSTAT Rx USA LLC1986-01-01Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-11-19Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-06-21Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2010-06-21Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralPliva Inc.1990-09-30Not applicableUs
Propranolol HydrochlorideSolution40 mg/5mLOralWest Ward Pharmaceuticals Corp.1987-05-15Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc1985-11-19Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralImpax Generics1990-09-30Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralAidarex Pharmaceuticals LLC2008-10-13Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralCardinal Health2004-03-04Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol HydrochlorideTablet20 mg/1Oralbryant ranch prepack1986-05-13Not applicableUs
Propranolol HydrochlorideInjection1 mg/mLIntravenousWest ward Pharmaceutical Corp2008-01-31Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralREMEDYREPACK INC.2011-10-132016-11-30Us
Propranolol HydrochlorideCapsule, extended release80 mg/1OralAvera Mc Kennan Hospital2015-05-15Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralPreferred Pharmaceuticals, Inc.2012-07-26Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2016-05-31Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralUDL Laboratories, Inc.1998-09-01Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralPhysicians Total Care, Inc.1996-12-09Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2016-09-08Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2011-05-242017-11-28Us
Propranolol HydrochlorideTablet40 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralCardinal Health2011-09-20Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralREMEDYREPACK INC.2011-04-19Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralCarilion Materials Management2008-10-13Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralUnit Dose Services2008-10-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2014-08-13Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralImpax Generics2016-09-19Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol HydrochlorideInjection1 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralPhysicians Total Care, Inc.2013-06-27Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralClinical Solutions Wholesale, Llc1990-09-30Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralTYA Pharmaceuticals2008-10-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralAvera Mc Kennan Hospital2015-04-08Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralA S Medication Solutions Llc2010-06-21Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-11-19Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-06-21Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralPliva Inc.1990-09-30Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralA S Medication Solutions2013-03-11Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2010-07-06Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralPhysicians Total Care, Inc.2006-03-30Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralPhysicians Total Care, Inc.1993-07-27Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralRebel Distributors Corp.2008-10-13Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2008-10-13Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol HydrochlorideTablet80 mg/1Oralbryant ranch prepack1986-05-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralA S Medication Solutions2010-06-21Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralImpax Generics2016-09-19Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralDIRECT RX2014-01-01Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralUnit Dose Services2008-10-13Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.1986-05-13Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralNu Care Pharmaceuticals, Inc.2010-06-21Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2016-11-30Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Propranolol HydrochlorideInjection, solution1 mg/mLIntravenousCardinal Health2003-02-26Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2011-04-282016-10-13Us
Propranolol HydrochlorideTablet10 mg/1Oralbryant ranch prepack2008-10-13Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2013-03-20Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralCarilion Materials Management2007-08-10Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralRebel Distributors Corp1986-01-01Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralAvera Mc Kennan Hospital2015-11-02Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralA S Medication Solutions Llc2010-06-21Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralA S Medication Solutions2013-03-11Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralMajor Pharmaceuticals2010-06-21Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralPhysicians Total Care, Inc.2007-03-30Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralClinical Solutions Wholesale2010-06-21Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralPhysicians Total Care, Inc.2007-02-05Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-11-19Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2010-11-082016-10-13Us
Propranolol HydrochlorideCapsule, extended release160 mg/1OralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralCarilion Materials Management1986-05-13Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralPliva Inc.1990-09-30Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralA S Medication Solutions1985-11-192016-10-19Us
Propranolol HydrochlorideTablet20 mg/1OralA S Medication Solutions1990-09-30Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2012-09-24Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralPhysicians Total Care, Inc.1995-08-18Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-03-11Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol HydrochlorideTablet40 mg/1Oralbryant ranch prepack2008-10-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralA S Medication Solutions Llc2010-06-21Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralA S Medication Solutions2010-06-21Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralImpax Generics2016-09-19Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralREMEDYREPACK INC.2011-06-032016-10-13Us
Propranolol HydrochlorideCapsule, extended release60 mg/1Oralbryant ranch prepack2007-08-10Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralAidarex Pharmaceuticals LLC2008-10-13Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralDispensing Solutions, Inc.2008-10-13Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralUnit Dose Services2007-08-10Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2015-06-18Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralA S Medication Solutions1990-09-30Not applicableUs
Propranolol HydrochlorideSolution20 mg/5mLOralAtlantic Biologicals Corps1987-05-15Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralCardinal Health2011-09-20Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.1986-05-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralRebel Distributors Corp1986-01-01Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol HydrochlorideSolution20 mg/5mLOralCarilion Materials Management1987-05-15Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralPliva Inc.1990-09-30Not applicableUs
Propranolol HydrochlorideSolution20 mg/5mLOralWest Ward Pharmaceuticals Corp.1987-05-15Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc1985-11-19Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralPhysicians Total Care, Inc.1994-03-14Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralCardinal Health2008-10-13Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-09-30Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralREMEDYREPACK INC.2011-04-192016-10-13Us
Propranolol HydrochlorideTablet40 mg/1OralProficient Rx LP1990-09-30Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralCarilion Materials Management2010-06-21Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol HydrochlorideTablet80 mg/1OralPliva Inc.1990-09-30Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralA S Medication Solutions1986-05-13Not applicableUs
Propranolol HydrochlorideTablet10 mg/1Oralbryant ranch prepack1990-09-30Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralREMEDYREPACK INC.2014-05-08Not applicableUs
Propranolol HydrochlorideCapsule, extended release160 mg/1OralPhysicians Total Care, Inc.2007-05-02Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralClinical Solutions Wholesale, Llc1990-09-30Not applicableUs
Propranolol HydrochlorideTablet60 mg/1OralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralTYA Pharmaceuticals2008-10-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release120 mg/1OralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralAvera Mc Kennan Hospital2015-04-21Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralA S Medication Solutions Llc2008-10-13Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralA S Medication Solutions2010-06-21Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralImpax Generics2016-09-19Not applicableUs
Propranolol HydrochlorideCapsule, extended release80 mg/1OralREMEDYREPACK INC.2011-07-282016-10-13Us
Propranolol HydrochlorideTablet20 mg/1Oralbryant ranch prepack2008-10-13Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralAidarex Pharmaceuticals LLC2008-10-13Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol HydrochlorideCapsule, extended release60 mg/1OralAvera Mc Kennan Hospital2015-03-11Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralUDL Laboratories, Inc.1998-09-01Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralPreferred Pharmaceuticals, Inc.2012-07-26Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralA S Medication Solutions1985-11-19Not applicableUs
Propranolol HydrochlorideTablet20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-23Not applicableUs
Propranolol HydrochlorideTablet10 mg/1OralPhysicians Total Care, Inc.2003-02-27Not applicableUs
Propranolol HydrochlorideTablet40 mg/1OralCardinal Health2011-09-20Not applicableUs
Propranolol HyrochlorideTablet10 mg/301OralNorthwind Pharmaceuticals2014-05-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AngilolNot Available
Bedranol SRNot Available
CardinolNot Available
CiplarNot Available
DeralinNot Available
DocitonNot Available
DuranolNot Available
InderalNot Available
IndoblocNot Available
INNOPRANNot Available
ProphyluxNot Available
SumialNot Available
Brand mixtures
NameLabellerIngredients
Inderide-40 TabWyeth Ayerst Canada Inc.
Inderide-80 TabWyeth Ayerst Canada Inc.
Propranolol Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Propranolol ScopolamineTps
Salts
Name/CASStructureProperties
Propranolol Hydrochloride
318-98-9
Thumb
  • InChI Key: ZMRUPTIKESYGQW-UHFFFAOYNA-N
  • Monoisotopic Mass: 295.13390666
  • Average Mass: 295.804
DBSALT000549
Categories
UNII9Y8NXQ24VQ
CAS number525-66-6
WeightAverage: 259.3434
Monoisotopic: 259.157228921
Chemical FormulaC16H21NO2
InChI KeyAQHHHDLHHXJYJD-UHFFFAOYSA-N
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
IUPAC Name
1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12
Pharmacology
IndicationFor the prophylaxis of migraine.
Structured Indications
PharmacodynamicsPropranolol, the prototype of the beta-adrenergic receptor antagonists, is a competitive, nonselective beta-blocker similar to nadolol without intrinsic sympathomimetic activity. Propanolol is a racemic compound; the l-isomer is responsible for adrenergic blocking activity.
Mechanism of actionPropranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Beta-3 adrenergic receptorProteinunknown
antagonist
HumanP13945 details
5-hydroxytryptamine receptor 1AProteinunknown
other/unknown
HumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknown
other/unknown
HumanP28222 details
Related Articles
AbsorptionPropranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals.
Volume of distribution
  • 4 L
Protein bindingMore than 90%
Metabolism

Hepatic

SubstrateEnzymesProduct
Propranolol
N-desisopropylpropranololDetails
Propranolol
4'-hydroxypropanololDetails
Route of eliminationPropranolol is extensively metabolized with most metabolites appearing in the urine.
Half life4 hours
ClearanceNot Available
ToxicitySymptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD50=565 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Propranolol Action PathwayDrug actionSMP00307
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Propranolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Propranolol.Experimental
AbirateroneThe serum concentration of Propranolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Propranolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Propranolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Propranolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Propranolol.Approved
AcetaminophenThe serum concentration of Propranolol can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamidePropranolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Propranolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Propranolol is combined with Acetylcholine.Approved
AcetyldigitoxinPropranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Propranolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Propranolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Propranolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Propranolol.Experimental, Investigational
AlbendazoleThe serum concentration of Propranolol can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.Approved
AldosteroneThe serum concentration of Propranolol can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Propranolol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Propranolol can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Propranolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Propranolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Propranolol is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Propranolol.Approved, Investigational
AlprenololPropranolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Propranolol can be increased when it is combined with Amantadine.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Propranolol.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Propranolol.Approved, Investigational
Ambroxol acefyllinatePropranolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostinePropranolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Propranolol is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Propranolol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllinePropranolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Propranolol.Approved, Investigational
AmitriptylineThe serum concentration of Propranolol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Propranolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Propranolol.Approved, Illicit
AmodiaquineThe metabolism of Propranolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Propranolol is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Propranolol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Propranolol can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Propranolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Propranolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Propranolol.Approved
AnvirzelPropranolol may increase the bradycardic activities of Anvirzel.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Propranolol.Approved
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Propranolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
AprepitantThe serum concentration of Propranolol can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutaminePropranolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Propranolol is combined with Arecoline.Experimental
ArformoterolPropranolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Propranolol.Approved, Investigational
ArmodafinilThe metabolism of Propranolol can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Propranolol is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Propranolol.Approved, Investigational
ArtemetherThe metabolism of Propranolol can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Propranolol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Propranolol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Propranolol.Approved
AtomoxetineThe metabolism of Propranolol can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Propranolol can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Propranolol.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Propranolol.Withdrawn
AzelastineThe serum concentration of Propranolol can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Propranolol is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Propranolol can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
BambuterolPropranolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Propranolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Propranolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Propranolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Propranolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Propranolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Propranolol.Withdrawn
BenzocaineThe serum concentration of Propranolol can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Illicit
BepridilThe serum concentration of Propranolol can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantPropranolol may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Propranolol.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Propranolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Propranolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Propranolol.Investigational
BexaroteneThe serum concentration of Propranolol can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostPropranolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Propranolol can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Propranolol.Investigational
BoceprevirThe metabolism of Propranolol can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Propranolol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Propranolol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Propranolol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propranolol.Approved
BretyliumBretylium may increase the bradycardic activities of Propranolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Propranolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Propranolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Propranolol.Investigational
BucindololPropranolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Propranolol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Propranolol.Approved, Investigational
BupranololPropranolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Propranolol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Propranolol can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Propranolol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Propranolol.Approved
CabergolinePropranolol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe serum concentration of Propranolol can be increased when it is combined with Caffeine.Approved
CalfactantPropranolol may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Propranolol.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Candesartan.Approved
CandoxatrilPropranolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Propranolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Propranolol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Propranolol is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Propranolol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Propranolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Propranolol.Approved
CarvedilolPropranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Propranolol can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Propranolol.Experimental
CelecoxibThe metabolism of Propranolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololPropranolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibPropranolol may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Propranolol.Withdrawn
CevimelineThe risk or severity of adverse effects can be increased when Propranolol is combined with Cevimeline.Approved
ChloramphenicolThe metabolism of Propranolol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Propranolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Propranolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Propranolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Propranolol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Propranolol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Propranolol.Approved
CholecalciferolThe metabolism of Propranolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Propranolol can be increased when it is combined with Cholesterol.Experimental
CholestyramineThe serum concentration of Propranolol can be decreased when it is combined with Cholestyramine.Approved
Cholic AcidThe serum concentration of Propranolol can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Propranolol can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Propranolol can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Propranolol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Propranolol.Approved
CitalopramThe serum concentration of Propranolol can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Propranolol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Propranolol can be decreased when combined with Clemastine.Approved
ClenbuterolPropranolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Propranolol.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Propranolol is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Propranolol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Propranolol.Approved, Investigational
ClomipramineThe serum concentration of Propranolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Propranolol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Propranolol.Approved, Nutraceutical
ClotrimazoleThe metabolism of Propranolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Propranolol.Approved
CobicistatThe serum concentration of Propranolol can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Propranolol.Approved
CocaineThe metabolism of Propranolol can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Propranolol.Approved
ColesevelamThe serum concentration of Propranolol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Propranolol can be decreased when it is combined with Colestipol.Approved
ColforsinThe serum concentration of Propranolol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Propranolol can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Propranolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Propranolol.Vet Approved
CrizotinibThe metabolism of Propranolol can be decreased when combined with Crizotinib.Approved
CryptenaminePropranolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Propranolol.Investigational
CyclophosphamideThe serum concentration of Propranolol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Propranolol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazidePropranolol may increase the hypotensive activities of Cyclothiazide.Approved
Cyproterone acetateThe serum concentration of Propranolol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Propranolol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propranolol.Approved
DabrafenibThe serum concentration of Propranolol can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Propranolol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Propranolol can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Propranolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Propranolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Propranolol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Propranolol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Propranolol can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Propranolol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Propranolol.Approved
DeferasiroxThe serum concentration of Propranolol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Propranolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Propranolol.Approved
DeserpidinePropranolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Propranolol is combined with Desflurane.Approved
DesipramineThe serum concentration of Propranolol can be increased when it is combined with Desipramine.Approved
DeslanosidePropranolol may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe serum concentration of Propranolol can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Propranolol can be increased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Propranolol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Vet Approved
DextromethorphanThe serum concentration of Propranolol can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Propranolol.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Propranolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Propranolol.Vet Approved
DiclofenacThe serum concentration of Propranolol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propranolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Propranolol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Propranolol.Approved
DigoxinThe serum concentration of Propranolol can be decreased when it is combined with Digoxin.Approved
DihydralazinePropranolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Propranolol.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Propranolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Propranolol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Propranolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinPropranolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Propranolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Propranolol.Approved
DobutaminePropranolol may decrease the bronchodilatory activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Propranolol.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Propranolol.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Propranolol.Approved
DorzolamidePropranolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinPropranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Propranolol can be increased when it is combined with Doxepin.Approved
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Propranolol.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Propranolol.Approved, Investigational
DoxorubicinThe serum concentration of Propranolol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Propranolol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Propranolol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Propranolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Propranolol.Approved
DroxidopaPropranolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetinePropranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Propranolol.Investigational
DyphyllinePropranolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Propranolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Propranolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Propranolol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Propranolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Propranolol.Approved
EfavirenzThe serum concentration of Propranolol can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipinePropranolol may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Propranolol can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Propranolol.Approved, Investigational
EliglustatThe metabolism of Propranolol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatPropranolol may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Propranolol can be decreased when it is combined with Enzalutamide.Approved
EphedraPropranolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Propranolol is combined with EPIBATIDINE.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Propranolol.Approved, Investigational
EpinephrinePropranolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Propranolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Propranolol is combined with Eplerenone.Approved
EpoprostenolPropranolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Eprosartan.Approved
Ergoloid mesylatePropranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovinePropranolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Propranolol.Approved, Investigational
ErythromycinThe metabolism of Propranolol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Propranolol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Propranolol.Approved
EsomeprazoleThe metabolism of Propranolol can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Propranolol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Propranolol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Propranolol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Propranolol can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Propranolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Propranolol.Approved, Investigational
EthanolThe serum concentration of Propranolol can be decreased when it is combined with Ethanol.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propranolol.Approved
EtodolacEtodolac may decrease the antihypertensive activities of Propranolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Propranolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
EtoperidoneThe serum concentration of Propranolol can be increased when it is combined with Etoperidone.Approved
EtoposideThe serum concentration of Propranolol can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
EtravirineThe serum concentration of Propranolol can be decreased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Propranolol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Propranolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Propranolol.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Propranolol.Approved
FelodipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Propranolol.Approved
FenoldopamPropranolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Propranolol.Approved
FenoterolPropranolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylThe serum concentration of Propranolol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Propranolol.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propranolol.Approved
FexofenadineThe serum concentration of Propranolol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Propranolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Fimasartan.Approved
FingolimodPropranolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Propranolol.Approved, Withdrawn
FluconazoleThe metabolism of Propranolol can be decreased when combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Propranolol.Vet Approved
FluoxetineThe metabolism of Propranolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Propranolol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Propranolol can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Propranolol can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Propranolol.Approved
FluvoxamineThe serum concentration of Propranolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolPropranolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Propranolol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Propranolol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propranolol.Approved
FosphenytoinThe metabolism of Propranolol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Propranolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Propranolol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Propranolol can be increased when it is combined with Fusidic Acid.Approved
GalantamineGalantamine may increase the bradycardic activities of Propranolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Propranolol.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Propranolol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Propranolol.Approved
GemfibrozilThe metabolism of Propranolol can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Propranolol can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Propranolol.Approved, Nutraceutical
GlibornuridePropranolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazidePropranolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePropranolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePropranolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidonePropranolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepidePropranolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideThe serum concentration of Propranolol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Propranolol can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Propranolol can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Propranolol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Propranolol.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Propranolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Propranolol.Approved
GuanethidinePropranolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
HaloperidolThe serum concentration of Propranolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Propranolol is combined with Halothane.Approved, Vet Approved
HexamethoniumPropranolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Propranolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Propranolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Propranolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Propranolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Propranolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Propranolol can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazidePropranolol may increase the hypotensive activities of Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Propranolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Propranolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Propranolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Propranolol.Approved
IdelalisibThe serum concentration of Propranolol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Propranolol.Approved, Investigational
ImatinibThe metabolism of Propranolol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Propranolol can be increased when it is combined with Imipramine.Approved
IndacaterolPropranolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Propranolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Indapamide.Approved
IndenololPropranolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Propranolol can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Propranolol can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Propranolol.Withdrawn
IndoraminPropranolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkPropranolol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Propranolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Propranolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Propranolol.Approved, Investigational
IsavuconazoniumThe metabolism of Propranolol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Propranolol.Approved
IsoetarinePropranolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Propranolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Propranolol.Approved, Withdrawn
IsoniazidThe metabolism of Propranolol can be decreased when combined with Isoniazid.Approved
IsoprenalinePropranolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Propranolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Propranolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Propranolol.Approved
ItraconazoleThe metabolism of Propranolol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradinePropranolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Propranolol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Propranolol can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Propranolol.Experimental
KetamineThe serum concentration of Propranolol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinPropranolol may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Propranolol.Approved
KetoconazoleThe metabolism of Propranolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Propranolol.Approved
LabetalolPropranolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineLacidipine may increase the hypotensive activities of Propranolol.Approved
LacosamidePropranolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Propranolol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Propranolol.Approved, Investigational
LanreotidePropranolol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Propranolol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Propranolol can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostPropranolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Propranolol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Propranolol.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Propranolol.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Propranolol.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Propranolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Propranolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Propranolol is combined with Levobupivacaine.Approved
LevodopaPropranolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Propranolol can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Propranolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Propranolol is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Propranolol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Propranolol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Propranolol.Approved
LiothyronineThe serum concentration of Propranolol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Propranolol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Propranolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Propranolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
LomitapideThe serum concentration of Propranolol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Propranolol can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Propranolol can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Propranolol can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Propranolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Propranolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Losartan.Approved
LovastatinThe metabolism of Propranolol can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Propranolol.Approved
LucinactantPropranolol may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Propranolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Propranolol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Propranolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
MacitentanPropranolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Propranolol.Approved
MalathionMalathion may increase the bradycardic activities of Propranolol.Approved, Investigational
ManidipinePropranolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Propranolol is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Propranolol can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Propranolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Propranolol.Withdrawn
MebendazoleThe serum concentration of Propranolol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Propranolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Propranolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Propranolol.Approved
Megestrol acetateThe serum concentration of Propranolol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Propranolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Propranolol.Approved, Vet Approved
MeprobamateThe serum concentration of Propranolol can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may decrease the antihypertensive activities of Propranolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Propranolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Propranolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Propranolol is combined with Methacholine.Approved
MethadoneThe serum concentration of Propranolol can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Propranolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Propranolol.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Propranolol.Approved
MethotrimeprazineThe metabolism of Propranolol can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propranolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Propranolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Propranolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Propranolol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Propranolol.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Propranolol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propranolol.Approved, Investigational
MetyrosinePropranolol may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Propranolol can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Propranolol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Propranolol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Propranolol can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrinePropranolol may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Propranolol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Propranolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Propranolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Propranolol.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Propranolol.Approved
MitomycinThe serum concentration of Propranolol can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Propranolol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Propranolol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Propranolol.Investigational
MoclobemideThe metabolism of Propranolol can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Propranolol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Propranolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Propranolol.Approved, Withdrawn
MorphineThe serum concentration of Propranolol can be increased when it is combined with Morphine.Approved, Investigational
MoxonidinePropranolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propranolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Propranolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Propranolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Propranolol.Approved
NadololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Propranolol.Investigational
NafcillinThe serum concentration of Propranolol can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the antihypertensive activities of Propranolol.Approved
NaftopidilPropranolol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Propranolol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Propranolol.Approved, Vet Approved
NaltrexoneThe serum concentration of Propranolol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
NaringeninThe serum concentration of Propranolol can be increased when it is combined with Naringenin.Experimental
NCX 4016NCX 4016 may decrease the antihypertensive activities of Propranolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Propranolol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Propranolol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Propranolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Propranolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Propranolol is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Propranolol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Propranolol can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Propranolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Propranolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Propranolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Propranolol.Approved
NiguldipinePropranolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Propranolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipinePropranolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Propranolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Propranolol.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Propranolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Propranolol.Approved
NitrazepamThe serum concentration of Propranolol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Propranolol can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Propranolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Propranolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Propranolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Propranolol.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Propranolol.Approved
NorepinephrinePropranolol may decrease the bronchodilatory activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Propranolol can be decreased when it is combined with Norethisterone.Approved
ObinutuzumabPropranolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Propranolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Propranolol.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Propranolol.Approved, Investigational
OlaparibThe metabolism of Propranolol can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propranolol.Approved, Investigational
OlodaterolPropranolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Propranolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Propranolol.Approved
OmapatrilatPropranolol may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Propranolol.Approved
OmeprazoleThe serum concentration of Propranolol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalinePropranolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Propranolol.Vet Approved
OsimertinibThe serum concentration of Propranolol can be increased when it is combined with Osimertinib.Approved
OuabainPropranolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Propranolol.Approved
OxprenololPropranolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Propranolol.Withdrawn
P-NitrophenolThe serum concentration of Propranolol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Propranolol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Propranolol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
Palmitic AcidThe serum concentration of Propranolol can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Propranolol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Propranolol can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Propranolol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Propranolol.Approved
PargylinePargyline may increase the hypotensive activities of Propranolol.Approved
ParoxetineThe metabolism of Propranolol can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePropranolol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Propranolol.Approved
Peginterferon alfa-2bThe serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Propranolol is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Propranolol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPropranolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Propranolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Propranolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Propranolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Propranolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Propranolol.Withdrawn
PhenobarbitalThe metabolism of Propranolol can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePropranolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Propranolol.Withdrawn
PhentolaminePropranolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
PhenylpropanolaminePropranolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Propranolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Propranolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Propranolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PimozideThe serum concentration of Propranolol can be increased when it is combined with Pimozide.Approved
PinacidilPropranolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Propranolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Propranolol is combined with Pipamperone.Approved
PirbuterolPropranolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Propranolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Propranolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Propranolol.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Propranolol.Withdrawn
Platelet Activating FactorThe serum concentration of Propranolol can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazidePropranolol may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Propranolol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Propranolol.Approved
Poractant alfaPropranolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Propranolol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Propranolol is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Propranolol.Approved
PrazosinPropranolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Propranolol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Propranolol.Approved, Vet Approved
PrimaquineThe metabolism of Propranolol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Propranolol can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Propranolol can be increased when it is combined with Probenecid.Approved
ProcaterolPropranolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Propranolol.Approved, Vet Approved
ProgesteroneThe serum concentration of Propranolol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Propranolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Propranolol can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Propranolol.Approved
PropafenoneThe serum concentration of Propranolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Propranolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propranolol is combined with Propofol.Approved, Investigational, Vet Approved
ProtriptylineThe serum concentration of Propranolol can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Propranolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Propranolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Propranolol.Approved
QuercetinThe serum concentration of Propranolol can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Propranolol is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Propranolol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Propranolol is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Propranolol can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Propranolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Propranolol.Approved
RanitidineThe serum concentration of Propranolol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Propranolol.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Propranolol.Approved
ReboxetineThe serum concentration of Propranolol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Propranolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Propranolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Propranolol.Approved
RescinnaminePropranolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Propranolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Propranolol.Experimental, Investigational
RifabutinThe metabolism of Propranolol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Propranolol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Propranolol can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Propranolol.Approved, Investigational
RilmenidinePropranolol may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Propranolol can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Propranolol is combined with Riociguat.Approved
RisperidonePropranolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrinePropranolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe metabolism of Propranolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabPropranolol may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Propranolol.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Propranolol.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Propranolol.Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Propranolol.Investigational, Withdrawn
RolapitantThe serum concentration of Propranolol can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Propranolol.Approved, Investigational
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Propranolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Propranolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Propranolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Propranolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Propranolol.Withdrawn
SalbutamolPropranolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Propranolol.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Propranolol.Approved, Vet Approved
SalmeterolPropranolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Propranolol.Approved
SaprisartanPropranolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Propranolol can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Propranolol can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Propranolol.Approved, Vet Approved
SelegilineThe serum concentration of Propranolol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Propranolol.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
SertralineThe serum concentration of Propranolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Propranolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Propranolol.Approved
SiltuximabThe serum concentration of Propranolol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Propranolol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Propranolol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Propranolol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Propranolol.Approved, Investigational
SitaxentanPropranolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Propranolol is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Propranolol.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Propranolol.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Propranolol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Propranolol.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Propranolol.Experimental
SpiraprilPropranolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Propranolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Propranolol.Investigational
St. John's WortThe serum concentration of Propranolol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Propranolol can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Propranolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Propranolol is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Propranolol can be decreased when it is combined with Streptozocin.Approved
SufentanilPropranolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Propranolol.Approved
SulfinpyrazoneThe serum concentration of Propranolol can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Propranolol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Propranolol.Approved
SumatriptanThe serum concentration of Propranolol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Propranolol can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Propranolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Propranolol.Withdrawn
TacrolimusThe serum concentration of Propranolol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
TamoxifenThe serum concentration of Propranolol can be decreased when it is combined with Tamoxifen.Approved
TamsulosinPropranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Propranolol can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Propranolol.Approved
TelaprevirThe metabolism of Propranolol can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Propranolol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Propranolol is combined with Telmisartan.Approved, Investigational
TemocaprilPropranolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Propranolol.Approved
TenofovirThe metabolism of Propranolol can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Propranolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Propranolol.Vet Approved
TerazosinPropranolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Propranolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalinePropranolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerfenadineThe serum concentration of Propranolol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Propranolol can be decreased when it is combined with Teriflunomide.Approved
TerlipressinPropranolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Propranolol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Propranolol can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Propranolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllinePropranolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Propranolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Propranolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Propranolol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propranolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Propranolol.Approved
TibolonePropranolol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Propranolol.Approved
TiclopidineThe metabolism of Propranolol can be decreased when combined with Ticlopidine.Approved
TicrynafenPropranolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Propranolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Propranolol.Investigational
TipranavirThe metabolism of Propranolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Propranolol.Approved
TocilizumabThe serum concentration of Propranolol can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Propranolol.Approved, Investigational
TolazamidePropranolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePropranolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePropranolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Propranolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Propranolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Propranolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Propranolol.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Propranolol.Approved
TopiramateThe metabolism of Propranolol can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Propranolol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Propranolol.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Propranolol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Propranolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Propranolol.Experimental
TranylcypromineThe metabolism of Propranolol can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Propranolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Propranolol.Approved
TrazodoneThe serum concentration of Propranolol can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Propranolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Propranolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Propranolol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Propranolol.Vet Approved
TrichlormethiazidePropranolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Propranolol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Propranolol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinPropranolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanPropranolol may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe serum concentration of Propranolol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Propranolol can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Propranolol.Approved
TroleandomycinThe serum concentration of Propranolol can be increased when it is combined with Troleandomycin.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Propranolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Propranolol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Propranolol.Approved
UnoprostonePropranolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Propranolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Propranolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Propranolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Propranolol is combined with Varenicline.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Propranolol.Approved
VemurafenibThe serum concentration of Propranolol can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Propranolol.Approved
VenlafaxineThe metabolism of Propranolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Propranolol is combined with Verapamil.Approved
VilanterolPropranolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinblastineThe serum concentration of Propranolol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Propranolol.Approved, Investigational
VincristineThe serum concentration of Propranolol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Propranolol can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetinePropranolol may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Propranolol.Approved
VoriconazoleThe metabolism of Propranolol can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Propranolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Propranolol.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Propranolol.Approved
ZileutonThe serum concentration of Propranolol can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Propranolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Propranolol can be decreased when combined with Ziprasidone.Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Propranolol.Approved, Investigational
ZomepiracZomepirac may decrease the antihypertensive activities of Propranolol.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take with food.
References
Synthesis Reference

DrugSyn.org

US3520919
General References
  1. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008 May;42(6):503-6. Epub 2007 Jun 22. [PubMed:17588604 ]
  2. Ohnishi ST, Sadanaga KK, Katsuoka M, Weidanz WP: Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes. Mol Cell Biochem. 1989 Nov 23-Dec 19;91(1-2):159-65. [PubMed:2695829 ]
  3. Singh N, Puri SK: Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 2000 Nov 2;77(2):185-93. [PubMed:11080509 ]
  4. Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K: Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 2006 Dec;3(12):e528. [PubMed:17194200 ]
External Links
ATC CodesC07BA05C07AA05C07FA05
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (256 KB)
MSDSDownload (74.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier-0.9031
Caco-2 permeable+0.6942
P-glycoprotein substrateSubstrate0.7079
P-glycoprotein inhibitor IInhibitor0.5588
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6463
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.924
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8487
Ames testNon AMES toxic0.9392
CarcinogenicityNon-carcinogens0.9097
BiodegradationNot ready biodegradable0.9871
Rat acute toxicity2.5625 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9185
hERG inhibition (predictor II)Inhibitor0.7092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akrimax pharmaceuticals llc
  • Glaxosmithkline llc
  • Actavis elizabeth llc
  • Inwood laboratories inc sub forest laboratories inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical
  • Upsher smith laboratories inc
  • Roxane laboratories inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hikma farmaceutica (portugal) sa
  • Sandoz canada inc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Morton grove pharmaceuticals inc
  • Wyeth ayerst laboratories
  • Clonmel healthcare ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Interpharm inc
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Northstar healthcare holdings ltd
  • Par pharmaceutical inc
  • Pliva inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Schering corp sub schering plough corp
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals
  • Warner chilcott div warner lambert co
  • Warner chilcott inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral120 mg
TabletOral40 mg
TabletOral80 mg
TabletOral20 mg
SolutionOral4.28 mg/mL
SolutionOral3.75 mg
LiquidIntravenous1 mg
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral160 mg
Capsule, extended releaseOral60 mg
Capsule, extended releaseOral80 mg
Capsule, extended releaseOral120 mg/1
Capsule, extended releaseOral160 mg/1
Capsule, extended releaseOral60 mg/1
Capsule, extended releaseOral80 mg/1
InjectionIntravenous1 mg/mL
Injection, solutionIntravenous1 mg/mL
SolutionOral20 mg/5mL
SolutionOral40 mg/5mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral50 mg/1
TabletOral60 mg/1
TabletOral80 mg/1
TabletOral
SolutionIntravenous1 mg
TabletOral10 mg/301
Prices
Unit descriptionCostUnit
Propranolol hcl powder11.63USD g
Propranolol 1 mg/ml vial10.0USD ml
Inderal la 160 mg capsule8.41USD capsule
Inderal LA 160 mg 24 Hour Capsule7.6USD capsule
Inderal la 160 mg capsule sa7.01USD capsule
Inderal la 120 mg capsule6.42USD capsule
Inderal LA 120 mg 24 Hour Capsule5.8USD capsule
Inderal la 120 mg capsule sa5.36USD capsule
Inderal la 80 mg capsule5.18USD capsule
Inderal LA 60 mg 24 Hour Capsule4.79USD capsule
Inderal LA 80 mg 24 Hour Capsule4.68USD capsule
Inderal la 60 mg capsule4.43USD capsule
Inderal la 80 mg capsule sa4.32USD capsule
Inderal la 60 mg capsule sa3.7USD capsule
Propranolol HCl CR 160 mg 24 Hour Capsule2.62USD capsule
InnoPran XL 80 mg 24 Hour Capsule2.5USD capsule
InnoPran XL 120 mg 24 Hour Capsule2.46USD capsule
Innopran xl 120 mg capsule2.41USD capsule
Innopran xl 80 mg capsule2.41USD capsule
Inderide 80-25 mg tablet2.17USD tablet
Propranolol HCl CR 120 mg 24 Hour Capsule2.0USD capsule
Inderide 40-25 mg tablet1.74USD tablet
Propranolol HCl CR 80 mg 24 Hour Capsule1.61USD capsule
Propranolol HCl CR 60 mg 24 Hour Capsule1.38USD capsule
Propranolol HCl 60 mg tablet1.27USD tablet
Inderal-La 160 mg Sustained-Release Capsule1.26USD capsule
Inderal-La 120 mg Sustained-Release Capsule1.07USD capsule
Inderal-La 80 mg Sustained-Release Capsule0.69USD capsule
Propranolol HCl 80 mg tablet0.66USD tablet
Propranolol-HCTZ 80-25 mg tablet0.65USD tablet
Inderal-La 60 mg Sustained-Release Capsule0.62USD capsule
Propranolol-HCTZ 40-25 mg tablet0.61USD tablet
Propranolol 80 mg tablet0.58USD tablet
Propranolol 60 mg tablet0.56USD tablet
Propranolol HCl 40 mg tablet0.53USD tablet
Propranolol 40 mg tablet0.45USD tablet
Propranolol HCl 20 mg tablet0.36USD tablet
Propranolol 20 mg tablet0.33USD tablet
Apo-Propranolol 120 mg Tablet0.32USD tablet
Propranolol HCl 10 mg tablet0.29USD tablet
Propranolol 10 mg tablet0.22USD tablet
Propranolol HCl 20 mg/5ml Solution0.11USD ml
Apo-Propranolol 80 mg Tablet0.06USD tablet
Novo-Pranol 80 mg Tablet0.06USD tablet
Pms-Propranolol 80 mg Tablet0.06USD tablet
Apo-Propranolol 20 mg Tablet0.04USD tablet
Apo-Propranolol 40 mg Tablet0.04USD tablet
Novo-Pranol 20 mg Tablet0.04USD tablet
Novo-Pranol 40 mg Tablet0.04USD tablet
Apo-Propranolol 10 mg Tablet0.02USD tablet
Novo-Pranol 10 mg Tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6500454 No2001-10-042021-10-04Us
US8338489 No2008-10-162028-10-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point96 °CPhysProp
water solubility61.7 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP3.48AVDEEF,A (1997)
Caco2 permeability-4.58ADME Research, USCD
pKa9.42SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0794 mg/mLALOGPS
logP3.03ALOGPS
logP2.58ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity76.83 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-03di-0090000000-f8c39664b694f5784865View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-05fr-9000000000-84923a2dc3053801527aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0fk9-2932000000-fa245a17a643ef33a0b2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-03di-0090000000-ee9d9c871e322202a948View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-03di-0290000000-9f3f72a6b6b792659137View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-0avi-5900000000-95293e6a5f843d0cc282View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-0ab9-9700000000-6b5b9e9743cb3f7bca58View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-0adi-9700000000-f5825268222d45a4ce95View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0159-1900000000-9872255282c6a95633aaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-00di-9500000000-122203085c028de6cbe4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0aor-0900000000-39e75b6ae19b4763a0bfView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-004i-0900000000-b75e7bf7aa20ce854157View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-00di-9200000000-2f102916e2fe0f6c1f4bView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Lewis CJ, Gong H, Brown MJ, Harding SE: Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology. Br J Pharmacol. 2004 Mar;141(5):813-24. Epub 2004 Feb 2. [PubMed:14757703 ]
  3. Rouget C, Barthez O, Goirand F, Leroy MJ, Breuiller-Fouche M, Rakotoniaina Z, Guerard P, Morcillo EJ, Advenier C, Sagot P, Cabrol D, Dumas M, Bardou M: Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia. Biol Reprod. 2006 Jan;74(1):209-16. Epub 2005 Sep 21. [PubMed:16177222 ]
  4. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
  5. Rezmann-Vitti LA, Louis SN, Nero TL, Jackman GP, Machida CA, Louis WJ: Site-directed mutagenesis of the rat beta1-adrenoceptor. Involvement of Tyr356 (7.43) in (+/-)cyanopindolol but not (+/-)[125Iodo]cyanopindolol binding. Eur J Med Chem. 2004 Jul;39(7):625-31. [PubMed:15236843 ]
  6. Yazawa K, Wang JW, Hao LY, Onoue Y, Kameyama M: Verrucotoxin, a stonefish venom, modulates calcium channel activity in guinea-pig ventricular myocytes. Br J Pharmacol. 2007 Aug;151(8):1198-203. Epub 2007 Jun 18. [PubMed:17572694 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Isaza C, Henao J, Ramirez E, Cuesta F, Cacabelos R: Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Methods Find Exp Clin Pharmacol. 2005 May;27(4):237-44. [PubMed:16082424 ]
  2. Rouget C, Barthez O, Goirand F, Leroy MJ, Breuiller-Fouche M, Rakotoniaina Z, Guerard P, Morcillo EJ, Advenier C, Sagot P, Cabrol D, Dumas M, Bardou M: Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia. Biol Reprod. 2006 Jan;74(1):209-16. Epub 2005 Sep 21. [PubMed:16177222 ]
  3. Illingworth CJ, Gooding SR, Winn PJ, Jones GA, Ferenczy GG, Reynolds CA: Classical polarization in hybrid QM/MM methods. J Phys Chem A. 2006 May 25;110(20):6487-97. [PubMed:16706406 ]
  4. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Berg T, Piercey BW, Jensen J: Role of beta1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension. 2010 May;55(5):1224-30. doi: 10.1161/HYPERTENSIONAHA.109.149286. Epub 2010 Mar 15. [PubMed:20231523 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Smejkal-Jagar L, Boranic M: Serotonin and serotoninergic agents affect proliferation of normal and transformed lymphoid cells. Immunopharmacol Immunotoxicol. 1995 Feb;17(1):151-62. [PubMed:7759768 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Bailey SR, Elliott J: Evidence for different 5-HT1B/1D receptors mediating vasoconstriction of equine digital arteries and veins. Eur J Pharmacol. 1998 Aug 21;355(2-3):175-87. [PubMed:9760032 ]
  2. Choppin A, O'Connor SE: Presence of vasoconstrictor 5HT1-like receptors revealed by precontraction of rabbit isolated mesenteric artery. Br J Pharmacol. 1995 Jan;114(2):309-14. [PubMed:7881730 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol. 1995 Apr;39(4):421-31. [PubMed:7640150 ]
  2. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  3. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659 ]
  6. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S: Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15. [PubMed:7895609 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol. 1995 Apr;39(4):421-31. [PubMed:7640150 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  2. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. [PubMed:15023456 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:40